...industry keeps its $80 billion agreement to provide savings and rebates. Its fees, to be divided among companies such as Pfizer <PFE.N> and Merck & Co <MRK.N>, would be delayed from 2010 to 2011, increasing from the initial $2.3 billion a year to $2.7 billion. ...

...such as health insurer WellPoint Inc. of Indianapolis, medical-device maker Medtronic Inc. of Minneapolis and drugmaker Pfizer Inc. of New York will get millions of new customers with the extension of coverage. Their industries will also face billions of dollars...

...Barron’s comments on PC trends and improved chip sales. New six-core processor chip should increase sales to server companies. Pfizer looks like it may win bid for German generic firm Stada. Healthcare bill should help big pharma companies hold current prices...

...or you are a pretty big flunky for the Democratic party, and don't know where you should really stand. Damn it. We voted them in, Pfizer didn't! I use to pass by the local free clinic on my way to the office. Most mornings I saw a bone thin old homeless woman...

...of hearing bagpipes. I get chills." More than a dozen bagpipe bands participated in the parade that started at 1:30 p.m. from the Pfizer parking lot on North Middletown Road. It marched down East Central Avenue and was wind east on Crooked Hill Road and south...

...generic drug maker Teva Pharmaceutical Industries. Ms. Chen sees continued growth for its business as many brand drugs, such as Pfizer's blockbuster cholesterol pill Lipitor, lose patent protection over the next three to five years. Countries around the world...

...  Tanezumab apparently neutralizes NGF and puts a halt to this amped-up pain signal. The drug is in final clinical trials, and Pfizer management says it has blockbuster potential. That might mean financial blockbuster, but hopefully it will also mean relief...

...purposes. ¶ What Loucks, who was acting U.S. attorney in Boston until November, didn't know until years later was that Pfizer managers were breaking that pledge not to practice off-label marketing even before the ink was dry on their plea. On the morning of...

...it among the firm's top picks for "blockbuster potential". McMahon hopes it will be the first of many. Another potential from Pfizer is a drug based on work by British scientists who identified a genetic mutation several years ago that prevents those who...

...Inc, which is developing the therapy. Other teams are using fats or lipids to deliver the therapy to the treatment target. Pfizer last week announced a deal with Canadian biotech Tekmira Pharmaceuticals Corp <TKM.TO> for this type of delivery vehicle for...